Novartis has confirmed nine instances—seven of them newly disclosed—in which tumors have developed in children treated with its marketed spinal muscular atrophy gene therapy Zolgensma® (onasemnogene ...

Researchers say to their knowledge the study represents the largest study to date of PFAS exposure and breast cancer incidence, particularly for ER-tumors.

Its first program is an investigational therapy program for ornithine transcarbamylase deficiency, a rare, X-linked metabolic disorder.

Personalized grafts, bioinks, and off-the-shelf tissues are advancing regenerative medicine toward broader clinical use.

Lonza plans to more than double its U.S. footprint of CDMO sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was ...

Principal Scientist, USP While payload design will remain a primary focus, the next era of innovation in CGT may ultimately ...

Researchers say findings establish HOX genes as potential therapeutic targets for enhancing bone regeneration.

Despite this advance, conventional CRISPR-Cas9 systems may introduce potentially harmful DNA breaks and cannot easily be ...

Not all DNA damage is equal. Every time a cell divides, it has to copy its DNA, and some stretches of the genome are harder to copy than others. Cancer cells depend on a protective response to get ...

OGT’s SureSeq next-generation sequencing portfolio now includes automated library preparation workflows compatible with the Hamilton NGS STAR Line.

Study findings showed that the cancer cells organize themselves according to a consistent, predictable structural pattern across different patients.

Differing apheresis practices at collection sites have a significant impact on samples and, therefore, the quality of cell ...